Posted on 4/19/17
ContraVir Pharmaceuticals: Potentially Undervalued
Contravir Pharmaceuticals (NASDAQ:CTRV) is a biopharmaceutical company based in the United States focused on the commercialization of the treatment of Herpes Zoster (Shingles) and Hepatitis B. . . .
Posted on 4/19/17
Johnson & Johnson: No Surprises Here
Johnson & Johnson (NYSE:JNJ) is down around 3% after the healthcare products company reported disappointing Q117 results. The recent rally and the meager organic growth supports . . .
Posted on 4/19/17
Johnson & Johnson: Not Too Late To Take Chips Off The Table
Back on July 25th of last year I wrote an article recommending people 'ease off' medical conglomerate Johnson & Johnson. My reasoning was based mostly off . . .
Posted on 4/19/17
Johnson & Johnson Posts Sluggish Sales, Boosts Guidance on Actelion Deal
The healthcare industry is in constant flux, but Johnson & Johnson (NYSE:JNJ) aims to be a blue-chip stalwart for investors in the space to get wide-ranging . . .
Posted on 4/19/17
Interpace Announces Coverage of ThyraMIR with UnitedHealthcare
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced that UnitedHealthcare, the . . .
Posted on 4/18/17
Idera Pharmaceuticals Announces Organizational Update
CAMBRIDGE, Mass. and EXTON, Pa., April 18, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for . . .
Posted on 4/18/17
How Pfizer Inc. Makes Most of Its Money
Pfizer Inc. (NYSE:PFE) made a whopping $52.8 billion last year. To put that amount into perspective, imagine a stack of $1 bills that reaches the height . . .
Posted on 4/18/17
Will Johnson & Johnson Earnings Send the Stock to New Highs?
Many people know Johnson & Johnson (NYSE:JNJ) for its consumer products, but the healthcare giant's pharmaceutical business has become the most important component of its long-term . . .
Posted on 4/18/17
5 Things You Should Expect When Johnson & Johnson Reports Its Q1 Results Tomorrow
It's officially time once again, folks – earnings season is under way! As per the norm, healthcare conglomerate Johnson & Johnson (NYSE:JNJ) is more or less . . .
Posted on 4/17/17
Celgene Stock History: The Biotech's Path to Gigantic Gains
A quick analysis of Celgene Corporation (NASDAQ:CELG) stock history reveals three distinct stages with four stock splits along the way. These stages led to the company . . .
Posted on 4/17/17
Integra LifeSciences' Stock Split: Why It Accomplished Nothing
When Integra LifeSciences Holding Corporation (NASDAQ:IART) decided to do a 2-for-1 stock split on Jan. 4, 2017, the surgical products company no doubt thought the move . . .
Posted on 4/17/17
3 Things to Watch in the Stock Market This Week
Stocks shed more than a full percentage point last week to push the Dow Jones Industrial Average (DJINDICES:^DJI) and the S&P 500 (SNPINDEX:^GSPC) down to a . . .
Posted on 4/17/17
3 Big Reasons to Be Bullish on Biotech Stocks
While the biotech sector isn't for the faint of heart, we Fools think that it can be a mistake to avoid the industry altogether. So why . . .
Posted on 4/15/17
MedPro Healthcare Staffing Ranks As 2017 Top Place To Work In South Florida
MedPro Healthcare Staffing, a leading travel healthcare staffing agency that provides temporary and contract staffing services to healthcare facilities across the United States, has been named . . .
Posted on 4/14/17
Johnson & Johnson: Up Or Down From $125?
The headline from Bloomberg in early March was unequivocal.The news agency added that JNJ "was hit with six of the seven largest product-defect verdicts of 2016, . . .
Posted on 4/14/17
Physicians’ Education Resource Announces Collaboration with The Cancer Drug Development Forum
CRANBURY, N.J.--(BUSINESS WIRE)--Physicians’ Education Resource® (PER®) has become a collaborative partner with The Cancer Drug Development Forum (CDDF) for PER®’s 1st Annual European Congress on Genitourinary . . .
Posted on 4/12/17
Johnson & Johnson Investors: Get Ready For A 6-7% Raise This Spring
If you're searching for companies offering consistent earnings growth, you'll be hard-pressed to find anyone beating Johnson & Johnson (NYSE:JNJ). Last year it held, to my . . .
Posted on 4/12/17
Pfizer Isn't Just A Dividend Stock
(Logo credit)Pfizer (NYSE:PFE) has been an extremely generous company in the past when it comes to returning capital. It is not alone as a mega-cap pharma . . .
Posted on 4/12/17
Merck Stock History: The Drugmaker's Boom, Bust, and Bounce Back
Merck (NYSE:MRK) is known today as a pharmaceuticals industry leader with a market cap of over $170 billion and a solid dividend. But the stock didn't . . .
Posted on 4/12/17
eHealth Technologies Ranked Fifth Best Mid-Sized Company in the Rochester Metro Area 2017 Top Workplaces
eHealth Technologies, the leading provider of clinically informed referral solutions, has been named a 2017 Top Workplaces by The Rochester Democrat and Chronicle. The company was . . .
Posted on 4/11/17
Should I Buy Amgen Or Pfizer?
Whew! I just finished filing our 2016 tax return. It's so nice to get that load off my shoulders! Each year at tax time, we contribute . . .
Posted on 4/10/17
Pioneer Dr. Andrew Newberg to Speak on Neurotheology During April 23 Fundraiser
WHO: Andrew Newberg, MD, Director of Research at the Marcus Institute of Integrative Health at Thomas Jefferson UniversityWHAT: The Circle of Light Foundation is hosting "TranquiliTea," . . .
Posted on 4/10/17
3 Big Pharma Companies With the Best Pipelines
It's not the current product lineups that matter the most for big pharma companies. It's their pipelines.Three big pharma companies boasting the strongest pipelines are Johnson . . .
Posted on 4/10/17
There's Never Been A Better Time To Buy ADMA Biologics
ADMA Biologics (NASDAQ:ADMA) is a biopharmaceutical company developing superior products for immunodeficient patients at risk for infection. Its lead product candidate, RI-022 demonstrated positive results in . . .
Posted on 4/6/17
History Comes Back to Haunt Teva Pharmaceutical Industries, Sending Shares Down 8% in March
What happenedShares of Teva Pharmaceutical Industries (NYSE:TEVA), an Israeli-based producer of generic and branded drugs, sank another 8% in March, according to data from S&P Global . . .

